All In Biotech

NDA 214927 · Zevra Denmark

Miplyffa

Arimoclomol Citrate · Oral

NovelBreakthrough therapyPriority reviewOrphan

CDER novel approval, Sep 20, 2024: To treat Niemann-Pick disease type C

Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Sep 20, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

6 Phase 3, 0 recruiting

FAERS reports

46

16 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 18, 2026.

MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. ( 1 )

Mechanism: The mechanism(s) by which arimoclomol exerts its clinical effects in patients with NPC is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 20, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
4 products under this application
  • MIPLYFFA · ARIMOCLOMOL CITRATE EQ 124MG BASE · CAPSULE, ORAL · Prescription
  • MIPLYFFA · ARIMOCLOMOL CITRATE EQ 62MG BASE · CAPSULE, ORAL · Prescription
  • MIPLYFFA · ARIMOCLOMOL CITRATE EQ 93MG BASE · CAPSULE, ORAL · Prescription
  • MIPLYFFA · ARIMOCLOMOL CITRATE EQ 47MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Arimoclomol" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6
  • vomiting5
  • product size issue4
  • insomnia3
  • pneumonia aspiration3
  • death2
  • fall2
  • fatigue2
  • gait disturbance2
  • pneumonia2
  • product administration interrupted2
  • product distribution issue2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20211
202539
20266

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Miplyffa (Arimoclomol Citrate)

2024 spending

$1.9M

Beneficiaries

13

18 claims

Per beneficiary

$143,884

$1,199.04 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,870,497

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Zevra Denmark

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.